Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized phase III trial to compare epirubicin and cyclophosphamide (EC) followed by docetaxel (T) to epirubicin and docetaxel (ET) followed by capecitabine (X) as adjuvant treatment for operable, node positive breast cancer patients

Next Previous
Trial Profile

Multicenter, randomized phase III trial to compare epirubicin and cyclophosphamide (EC) followed by docetaxel (T) to epirubicin and docetaxel (ET) followed by capecitabine (X) as adjuvant treatment for operable, node positive breast cancer patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
  • Indications Early breast cancer; HER2 negative breast cancer
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
  • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
  • 29 Oct 2005 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top